TriNetX and Regeneron announced a strategic collaboration to accelerate drug discovery and digital health innovation through an expanded EHR-linked database. The partnership will allow Regeneron to access de-identified electronic health records from approximately 300 million patients worldwide through TriNetX’s global network (170 million of whom are in the United States). Moreover, this large-scale integration will significantly strengthen the company’s EHR-linked database, which already supports advanced genomic and proteomic research initiatives.
TriNetX will provide secure, licensed access to its anonymized data, which originates from healthcare systems across multiple countries and regions. Consequently, Regeneron will combine these datasets with its existing genomic and proteomic resources to expand its EHR-linked database and improve research precision.
Additionally, the collaboration gives Regeneron an exclusive opportunity to connect large-scale molecular datasets with TriNetX’s phenotypic health records. Therefore, the integrated EHR-linked database will enable researchers to uncover deeper insights into disease progression, treatment outcomes, and patient responses across diverse populations.
The companies emphasized that they will follow strict privacy regulations while managing sensitive patient information. Furthermore, they will use privacy-preserving technologies to ensure that all data within the EHR-linked database remains anonymized and compliant with global standards such as HIPAA and GDPR.
Regeneron’s Genetics Center has developed one of the largest repositories for genomic sequencing (higher resolution DNA) and proteomics data. With the addition of TriNetX Network as an input to EHR-linked studies, the Genetics Center anticipates increasing its EHR-linked repository size substantially while improving its ability to identify new drug targets and new biomarkers.
In addition, the partnership would help in developing AI models that are designed to revolutionize healthcare delivery processes. In this way, the enhanced EHR-linked database would serve as an excellent source of training material for AI models and would facilitate better predictions, timely diagnoses, and tailored healthcare interventions.
Senior executives at both companies acknowledged the importance of leveraging their real-world data along with advanced analytics. On the other hand, TriNetX announced that its federated data network would expand continuously.
Regeneron also plans to invest up to $200 million in TriNetX as part of the agreement, reinforcing its commitment to data-driven innovation. Consequently, this financial support will help expand infrastructure, improve analytics capabilities, and accelerate the growth of the EHR-linked database platform.
Industry analysts believe that such collaborations mark a turning point in life sciences research, where data integration plays a central role. Therefore, the combined EHR-linked database could enable faster clinical trials, more efficient drug development pipelines, and improved patient outcomes across global healthcare systems.
Furthermore, the partnership aligns with broader trends in digital health, where organizations increasingly rely on real-world evidence and large datasets. As healthcare providers adopt more data-centric approaches, the importance of a robust EHR-linked database continues to grow in both clinical and commercial applications.
Looking ahead, both companies aim to leverage this collaboration to pioneer next-generation therapies and digital health solutions. Ultimately, the expanded EHR-linked database will serve as a critical foundation for innovation, helping researchers predict, prevent, and manage diseases more effectively across diverse populations.
